Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study.
Rowan CR, Keegan D, Byrne K, Cullen G, Mulcahy HE, Sheridan J, Ryan EJ, de Vries A, D'Haens G, Doherty GA.
Neutrophil extracellular trap induced by HMGB1 exacerbates damages in the ischemic brain.
Kim SW, Lee H, Lee HK, Kim ID, Lee JK.
Acta Neuropathol Commun. 2019 Jun 10;7(1):94. doi: 10.1186/s40478-019-0747-x.
PMID:31177989
[Ketamine].
Reboso Morales JA, González Miranda F.
Rev Esp Anestesiol Reanim. 1999 Mar;46(3):111-22.
PMID:10228376
Chelonian Sedation and Anesthesia.
Scarabelli S, Di Girolamo N.
Vet Clin North Am Exot Anim Pract. 2022 Jan;25(1):49-72. doi: 10.1016/j.cvex.2021.08.009.
PMID:34823698
The Human Experience with Intravenous Levodopa.
Siddiqi SH, Abraham NK, Geiger CL, Karimi M, Perlmutter JS, Black KJ.
Front Pharmacol. 2016 Jan 6;6:307. doi: 10.3389/fphar.2015.00307. eCollection 2015.
PMID:26779024
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H.